Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Data from observational investigations, including studies of genetic variants, provide evidence consistent with a causal relationship between elevations in TG and TGRL-C and greater risk for ASCVD. Randomized controlled trial evidence of ASCVD risk reduction with therapies that substantially lower TG and TGRL-C is limited by the fact that no large-scale trial results have been published from a study that enrolled subjects selected specifically on the basis of TG or TGRL-C elevation, although three such trials are underway or in the planning stages. Subgroup analyses from randomized controlled trials are suggestive of a reduction in coronary heart disease and ASCVD event rates with statins, fibrates, omega-3 fatty acid concentrates, and niacin in subjects with elevated TGs, particularly if accompanied by low high-density lipoprotein-cholesterol. Mechanistic studies also support the biologic plausibility of this relationship. SUMMARY: In conclusion, the available data are suggestive of a benefit of ASCVD reduction with therapies that lower TG and TGRL-C; results from ongoing outcomes trials are expected to provide definitive evidence of this relationship.
|
Authors | Kevin C Maki, Mary R Dicklin |
Journal | Current opinion in lipidology
(Curr Opin Lipidol)
Vol. 28
Issue 4
Pg. 374-379
(Aug 2017)
ISSN: 1473-6535 [Electronic] England |
PMID | 28441155
(Publication Type: Journal Article, Review)
|
Chemical References |
- Hypolipidemic Agents
- Triglycerides
|
Topics |
- Cardiovascular Diseases
(epidemiology, genetics, metabolism)
- Genetic Variation
- Humans
- Hypolipidemic Agents
(pharmacology)
- Risk
- Triglycerides
(metabolism)
|